Biogen, Eisai releases four-year data on aducanumab; EMA stamps Eidos' aTTR therapy with orphan designation
→ After an attempt to resurrect faith in their Alzheimer’s drug BAN2401, using a small subset of patients from a closely watched Phase II trial …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
